Report: States scale back funding to HIV, AIDS medication programs
NEW YORK — Several states are cutting funding to programs that provide HIV medications to people who can’t afford them in an effort to reduce spending, according to a published report.
The Washington Post reported that more than 8,300 people are on waiting lists to obtain antiretrovirals and other drugs that treat HIV, AIDS and related conditions. The Post article highlighted particularly large program cuts in Illinois and Georgia, as well as one proposed for Florida.
The programs are designed for patients who can’t afford HIV/AIDS drugs, lack insurance or have limited coverage.
Lilly inks deal with Care Capital, NovaQuest Capital to establish BioCritica
INDIANAPOLIS — Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.
Lilly signed a deal with Care Capital and NovaQuest Capital to establish BioCritica, a privately held biotechnology company that will focus on continued U.S. development and commercialization of the severe sepsis treatment Xigris (drotrecogin alfa [activated]). The new company also will expand its portfolio of critical care medicines for hospitals.
Under a licensing agreement, BioCritica will acquire U.S. development and commercialization rights to Xigris and receive rights to potentially acquire several critical care compounds in preclinical development at Lilly.
PhRMA: California-based drug makers focusing on heart disease, cancer treatments
WASHINGTON — California-based companies are developing nearly more than one-fifth of the drugs to treat some of the deadliest diseases in the world, according to an analysis by the drug industry lobby.
According to two Pharmaceutical Research and Manufacturers of America reports released this year, of the 1,186 drugs under development for heart disease and cancer, 243 were from California companies. These include 188-of-the-887 drugs for more than 20 types of cancer, and 55-of-the-299 drugs for heart disease and stroke.
“California’s companies are on the front line in both the ongoing war on cancer and the intense fight against heart disease,” PhRMA spokesman Jeff Trewhitt said. “The drugs they are testing could prove to be important to patients all over the world, including [patients in] both the United States and California, where heart disease and cancer are also the two leading causes of death.”
According to PhRMA, more than 73,000 California residents died of heart disease in 2004, and heart disease, stroke, diabetes and cancer accounted for 54% of deaths among the state’s growing Latino population.